Clinical Trials
11 trialsNCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04969835 2026-05-15
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting